2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2023
Cancer incidence among incarcerated and formerly incarcerated individuals: A statewide retrospective cohort study
Aminawung J, Soulos P, Oladeru O, Lin H, Gonsalves L, Puglisi L, Hassan S, Richman I, Wang E, Gross C. Cancer incidence among incarcerated and formerly incarcerated individuals: A statewide retrospective cohort study. Cancer Medicine 2023, 12: 15447-15454. PMID: 37248772, PMCID: PMC10417084, DOI: 10.1002/cam4.6162.Peer-Reviewed Original ResearchConceptsNon-Hispanic Black individualsScreen-detectable cancersStandardized incidence ratiosNon-Hispanic white individualsCancer incidenceGeneral populationStatewide retrospective cohort studyRetrospective cohort studyWhite individualsState tumor registryLower cancer incidenceBlack individualsHigher cancer incidenceIncarceration exposureCohort studyRetrospective cohortTumor RegistryIncidence ratiosIncarcerated individualsCancer screeningIncidence rateHigh incidenceConnecticut residentsEthnic strataIncidence
2019
Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.
Yang D, Makarov D, Gross C, Yu J. Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening. Journal Of Clinical Oncology 2019, 37: 1567-1567. DOI: 10.1200/jco.2019.37.15_suppl.1567.Peer-Reviewed Original ResearchProstate cancer incidenceHealth service areasMetastatic prostate cancerMetastatic prostate cancer incidenceMetastatic diseaseCancer incidenceProstate cancerLocalized diseasePopulation-weighted linear regressionMen 70 yearsEnd Results (SEER) databaseHealth Service regionResults databaseIncidence rateHospital careMetastatic incidenceIncidenceDiseaseCancerLate increasePSALinear regressionMenTemporal relationshipSurveillance
2014
Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications
Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal Of The National Cancer Institute 2014, 106: dju159. PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.Peer-Reviewed Original ResearchConceptsEnd Results-MedicareBreast cancer stageCohort of womenEarly-stage tumorsBreast cancer screeningAdjunct imagingSignificant changesCancer screeningCancer stageIncidence rateBreast cancerAdjunct procedureOlder womenMedicare populationMedicare beneficiariesClinical practiceComputer-aided detectionPoisson regressionNational feeCohortBreast ultrasoundWomenEarlier cohortsLater cohortsMedicare spending